Daniel Lynch - Feb 20, 2025 Form 4 Insider Report for SpringWorks Therapeutics, Inc. (SWTX)

Role
Director
Signature
/s/ Francis I. Perier, Jr. as Attorney-in Fact
Stock symbol
SWTX
Transactions as of
Feb 20, 2025
Transactions value $
-$2,866,534
Form type
4
Date filed
2/24/2025, 06:57 PM
Previous filing
Feb 19, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SWTX Common Stock Sale -$2.65M -44K -33.72% $60.14 86.5K Feb 20, 2025 Direct F1, F2
transaction SWTX Common Stock Sale -$219K -3.58K -4.14% $61.24 82.9K Feb 20, 2025 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on May 3, 2024.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.68. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.16 to $61.45. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.